#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16328	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2244	724.2	0	.	n	.	0	A69G	SNP	69	69	A	339	339	G	837	G,A	775,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16328	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2244	724.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1720	1720	T	902	T,C	816,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16328	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2244	724.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1454	1454	C	937	C	882	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30130	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3505	856.7	0	.	n	.	0	T695C	SNP	695	695	T	1014	1014	C	918	C	855	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30130	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3505	856.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2290	2290	C	954	C,A	881,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30130	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3505	856.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2364	2364	A	963	A	894	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30130	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3505	856.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	2916	2916	C	991	C,T	936,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2248	folP	855	855	100.0	folP.l15.c4.ctg.1	1619	138.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1117	1119	AGC	245;239;240	A;G;C	228;223;222	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6922	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3449	200.2	1	SNP	p	S91F	1	.	.	271	273	TTC	561	563	TTC	223;223;223	T;T;C	209;210;210	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6922	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3449	200.2	1	SNP	p	D95G	1	.	.	283	285	GGC	573	575	GGC	222;223;222	G;G;C	210;211;207	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6922	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3449	200.2	1	SNP	p	G95N	0	.	.	283	285	GGC	573	575	GGC	222;223;222	G;G;C	210;211;207	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1846	mtrR	633	633	99.84	mtrR.l15.c17.ctg.1	1177	155.4	0	.	p	.	0	D79N	NONSYN	235	237	GAT	520	522	AAT	237;234;230	A;A;T,C	223;221;214,1	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1846	mtrR	633	633	99.84	mtrR.l15.c17.ctg.1	1177	155.4	1	SNP	p	G45D	0	.	.	133	135	GGC	418	420	GGC	214;214;216	G;G,T;C	201;197,1;203	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	912	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c17.ctg.1	1040	87.3	0	.	n	.	0	A197.	DEL	197	197	A	570	570	A	215	A	203	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5432	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2980	181.7	0	.	p	.	0	E91G	NONSYN	271	273	GAG	613	615	GGG	204;205;206	G;G;G	186;187;187	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5432	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2980	181.7	1	SNP	p	D86N	0	.	.	256	258	GAC	598	600	GAC	206;205;206	G;A;C	195;189;194	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5432	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2980	181.7	1	SNP	p	S87I	0	.	.	259	261	AGT	601	603	AGT	206;205;205	A;G;T	194;193;191	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5432	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2980	181.7	1	SNP	p	S87R	0	.	.	259	261	AGT	601	603	AGT	206;205;205	A;G;T	194;193;191	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5432	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2980	181.7	1	SNP	p	S87W	0	.	.	259	261	AGT	601	603	AGT	206;205;205	A;G;T	194;193;191	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5432	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2980	181.7	1	SNP	p	S88P	0	.	.	262	264	TCC	604	606	TCC	204;205;206	T;C;C	191;192;193	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4940	parE	1986	1986	99.95	parE.l15.c30.ctg.1	2712	181.6	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1553	1555	CAC	269;269;272	C;A;C,T	253;251;255,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4940	parE	1986	1986	99.95	parE.l15.c30.ctg.1	2712	181.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1502	1504	GGC	293;289;291	G;G;C,A	273;271;269,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	27	4552	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2333	194.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1233	1235	GCA	248;246;248	G;C;A	229;227;230	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4552	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2333	194.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1236	1238	ATC	247;243;244	A;T;C	230;225;228	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4552	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2333	194.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1248	1250	GTG	245;246;252	G;T;G	226;224;230	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4552	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2333	194.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1248	1250	GTG	245;246;252	G;T;G	226;224;230	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4552	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2333	194.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1752	1754	ACC	216;217;215	A;C;C	197;206;204	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4552	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2333	194.5	1	SNP	p	T502V	0	.	.	1504	1506	ACG	1806	1808	ACG	220;220;223	A;C;G	182;183;182	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4552	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2333	194.5	1	SNP	p	T502P	0	.	.	1504	1506	ACG	1806	1808	ACG	220;220;223	A;C;G	182;183;182	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4552	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2333	194.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1929	1931	GGC	194;194;191	G,T;G;C	181,1;180;179	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4552	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2333	194.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1938	1940	GGC	189;190;188	G;G;C	175;173;174	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4552	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2333	194.5	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1956	1958	CTG	179;183;184	C,G;T;G,C	147,4;142;150,1	penA.44.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6564	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3149	207.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1720	1722	CCG	240;243;243	C;C;G	217;226;221	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2450	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1834	133.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	553	553	C	152	C	142	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3492	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	1614	214.5	0	.	p	.	0	T26A	NONSYN	76	78	ACC	443	445	GCC	286;290;289	G;C;C	266;267;269	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3492	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	1614	214.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	479	481	GAA	284;286;286	G;A;A	261;263;263	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3492	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	1614	214.5	0	.	p	.	0	N124S	NONSYN	370	372	AAT	737	739	AGT	267;264;266	A;G;T	252;249;247	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3492	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	1614	214.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	767	769	GAT	276;279;279	G;A;T	252;256;259	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3492	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	1614	214.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	890	892	TCA	294;295;293	T;C;A	268;267;270	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3492	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	1614	214.5	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1019	1021	GTC	290;288;287	G;T,G;C	274;268,1;271	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3492	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	1614	214.5	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1031	1033	TCT	280;282;278	T;C;T	264;266;263	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3492	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	1614	214.5	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1349	1351	GCA	288;291;298	G;C;A	269;269;273	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3492	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	1614	214.5	1	SNP	p	G120K	1	.	.	358	360	AAG	725	727	AAG	280;280;283	A,G;A;G	262,1;262;263	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3492	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	1614	214.5	1	SNP	p	D121N	0	.	.	361	363	GAC	728	730	GAC	282;281;278	G;A;C	263;259;258	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3492	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	1614	214.5	1	SNP	p	A121D	1	.	.	361	363	GAC	728	730	GAC	282;281;278	G;A;C	263;259;258	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	12268	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	5014	244.3	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2105	2107	CAT	266;266;265	C;A;T	244;248;244	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1328	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1158	114.5	1	SNP	p	V57M	1	.	.	169	171	ATG	583	585	ATG	282;281;279	A;T;G	268;264;265	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
